---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-182137"
form_type: "8-K"
ticker: "ERAS"
cik: "0001761918"
company_name: "Erasca, Inc."
filed_at: "2026-04-27T23:59:59+00:00"
generated_at: "2026-05-15T03:54:12.242666+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Erasca reports positive Phase 1 data for pan-RAS glue ERAS-0015: 62% uORR in 2L+ KRAS G12X NSCLC

## Summary
- 62% unconfirmed ORR at 8 weeks in 2L+ KRAS G12X NSCLC at PADs 16-32 mg QD (N=37), exceeding RMC-6236 by 24 ppt.
- 40% unconfirmed ORR at 14 weeks in 2L KRAS G12X PDAC at PADs (N=20), exceeding comparator by 11 ppt.
- 100% of patients (14/14) at PADs showed ≥75% reduction in KRAS G12X ctDNA; 5 showed 100% reduction.
- No DLTs; well-tolerated with no discontinuations due to TRAEs; one Grade 5 pneumonitis event after withdrawal of care.
- Monotherapy RDEs set at 24 and 32 mg QD; expansion and combo dose escalation initiated ahead of guidance.

## SEC filing metadata
- accession: 0001193125-26-182137
- form_type: 8-K
- ticker: ERAS
- cik: 0001761918
- company_name: Erasca, Inc.
- filed_at: 2026-04-27T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1761918/000119312526182137/0001193125-26-182137-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1761918/000119312526182137/d126999d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-182137
- JSON: https://secwatch.observer/filing/0001193125-26-182137.json
- Plain text: https://secwatch.observer/filing/0001193125-26-182137.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.